guest ::
| Home > Publications database > Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. > print |
| Home > Publications database > Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. > print |
| 001 | 126496 | ||
| 005 | 20240228140828.0 | ||
| 024 | 7 | _ | |a 10.1158/0008-5472.CAN-13-3629 |2 doi |
| 024 | 7 | _ | |a pmid:25391241 |2 pmid |
| 024 | 7 | _ | |a 0008-5472 |2 ISSN |
| 024 | 7 | _ | |a 0099-7013 |2 ISSN |
| 024 | 7 | _ | |a 0099-7374 |2 ISSN |
| 024 | 7 | _ | |a 1538-7445 |2 ISSN |
| 024 | 7 | _ | |a altmetric:2883452 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-02525 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Faria, Claudia C |b 0 |
| 245 | _ | _ | |a Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. |
| 260 | _ | _ | |a Philadelphia, Pa. |c 2015 |b AACR |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1523538943_4530 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Medulloblastoma is the most common malignant pediatric brain tumor, with metastases present at diagnosis conferring a poor prognosis. Mechanisms of dissemination are poorly understood and metastatic lesions are genetically divergent from the matched primary tumor. Effective and less toxic therapies that target both compartments have yet to be identified. Here, we report that the analysis of several large nonoverlapping cohorts of patients with medulloblastoma reveals MET kinase as a marker of sonic hedgehog (SHH)-driven medulloblastoma. Immunohistochemical analysis of phosphorylated, active MET kinase in an independent patient cohort confirmed its correlation with increased tumor relapse and poor survival, suggesting that patients with SHH medulloblastoma may benefit from MET-targeted therapy. In support of this hypothesis, we found that the approved MET inhibitor foretinib could suppress MET activation, decrease tumor cell proliferation, and induce apoptosis in SHH medulloblastomas in vitro and in vivo. Foretinib penetrated the blood-brain barrier and was effective in both the primary and metastatic tumor compartments. In established mouse xenograft or transgenic models of metastatic SHH medulloblastoma, foretinib administration reduced the growth of the primary tumor, decreased the incidence of metastases, and increased host survival. Taken together, our results provide a strong rationale to clinically evaluate foretinib as an effective therapy for patients with SHH-driven medulloblastoma. |
| 536 | _ | _ | |a 312 - Functional and structural genomics (POF3-312) |0 G:(DE-HGF)POF3-312 |c POF3-312 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Anilides |2 NLM Chemicals |
| 650 | _ | 7 | |a GSK 1363089 |2 NLM Chemicals |
| 650 | _ | 7 | |a Hedgehog Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Quinolines |2 NLM Chemicals |
| 650 | _ | 7 | |a SHH protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Proto-Oncogene Proteins c-met |0 EC 2.7.10.1 |2 NLM Chemicals |
| 650 | _ | 7 | |a Receptor, Platelet-Derived Growth Factor beta |0 EC 2.7.10.1 |2 NLM Chemicals |
| 700 | 1 | _ | |a Golbourn, Brian J |b 1 |
| 700 | 1 | _ | |a Dubuc, Adrian M |b 2 |
| 700 | 1 | _ | |a Remke, Marc |b 3 |
| 700 | 1 | _ | |a Diaz, Roberto J |b 4 |
| 700 | 1 | _ | |a Agnihotri, Sameer |b 5 |
| 700 | 1 | _ | |a Luck, Amanda |b 6 |
| 700 | 1 | _ | |a Sabha, Nesrin |b 7 |
| 700 | 1 | _ | |a Olsen, Samantha |b 8 |
| 700 | 1 | _ | |a Wu, Xiaochong |b 9 |
| 700 | 1 | _ | |a Garzia, Livia |b 10 |
| 700 | 1 | _ | |a Ramaswamy, Vijay |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Mack, Stephen C |b 12 |
| 700 | 1 | _ | |a Wang, Xin |b 13 |
| 700 | 1 | _ | |a Leadley, Michael |b 14 |
| 700 | 1 | _ | |a Reynaud, Denis |b 15 |
| 700 | 1 | _ | |a Ermini, Leonardo |b 16 |
| 700 | 1 | _ | |a Post, Martin |b 17 |
| 700 | 1 | _ | |a Northcott, Paul A |0 P:(DE-HGF)0 |b 18 |
| 700 | 1 | _ | |a Pfister, Stefan |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 19 |u dkfz |
| 700 | 1 | _ | |a Croul, Sidney E |b 20 |
| 700 | 1 | _ | |a Kool, Marcel |0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8 |b 21 |u dkfz |
| 700 | 1 | _ | |a Korshunov, Andrey |0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93 |b 22 |u dkfz |
| 700 | 1 | _ | |a Smith, Christian A |b 23 |
| 700 | 1 | _ | |a Taylor, Michael D |b 24 |
| 700 | 1 | _ | |a Rutka, James T |b 25 |
| 773 | _ | _ | |a 10.1158/0008-5472.CAN-13-3629 |g Vol. 75, no. 1, p. 134 - 146 |0 PERI:(DE-600)2036785-5 |n 1 |p 134 - 146 |t Cancer research |v 75 |y 2015 |x 1538-7445 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:126496 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 21 |6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 22 |6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |2 G:(DE-HGF)POF3-300 |v Functional and structural genomics |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER RES : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCER RES : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)G380-20160331 |k G380 |l KKE Neuropathologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G380-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|